[{"data":1,"prerenderedAt":162},["ShallowReactive",2],{"content-route-/en/research/chronic-disseminated-candidiasis-iris-cohort-2026":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":144,"alternates":153},"target","/en/research/chronic-disseminated-candidiasis-iris-cohort-2026","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":58,"body":62},"Chronic disseminated candidiasis and suspected IRIS: 2026 cohort","Chronic disseminated candidiasis cohort of 111 adults: early imaging progression and suspected IRIS during treatment do not validate Candida die-off.","2026-10-09","Initial summary of a retrospective cohort, with a bounded distinction between suspected CDC-IRIS and consumer Candida die-off.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":40,"limitations":47,"practicalChange":57},"reinhold-chronic-disseminated-candidiasis-iris-cohort-2026","Retrospective multinational observational cohort","Adults with possible, probable, or proven chronic disseminated candidiasis treated with antifungals; 109 of 111 had hematologic or oncologic disease.","111 adults from 19 countries","contextual","The cohort documents a narrow, medically managed immune-reconstitution context for treatment-period imaging progression. It does not test self-managed interventions or validate Candida die-off.","/en/research/evidence/broad-candida-claims","No dedicated external study funding was reported. FungiScope received unrestricted registry-maintenance and infrastructure grants from Basilea Pharmaceutica, Melinta Therapeutics LLC, Mundipharma Ltd., and Pfizer Inc; these funders had no role in study design, conduct or analysis, interpretation, manuscript preparation, or submission.","Authors reported individual grants, consulting fees, honoraria, speaker fees, travel or meeting support, advisory roles, research support, and one patent across pharmaceutical, antifungal, diagnostic, academic, and public-funding organizations. The remaining authors reported no competing interests related to the manuscript.","2026-09-16",[38,39],"At the first follow-up scan, obtained at a median of 14 days (IQR 7–24), 28 of 74 evaluable patients had imaging progression (37.8%), 26 of 74 were stable (35.1%), 17 of 74 improved (23.0%), and 3 of 74 had a complete response (4.1%). The authors interpreted early progression as likely paradoxical worsening during neutrophil recovery rather than antifungal failure.","Corticosteroids were used for suspected chronic-disseminated-candidiasis immune-reconstitution inflammatory syndrome (CDC-IRIS) in 5 of 111 patients (4.5%). The reports described paradoxical radiological progression with persistent fever at a mean of 29 days after diagnosis, typically during neutrophil recovery; the cases were not defined or centrally adjudicated using a standard protocol.",{"appliesTo":41,"doesNotApplyTo":44},[42,43],"Adults with diagnosed, medically treated chronic disseminated candidiasis, most of whom had hematologic or oncologic disease.","Interpretation of early imaging progression in the clinical context of neutrophil recovery.",[45,46],"Self-attributed broad Candida symptoms or self-managed antifungals, supplements, cleanses, or restrictive diets.","Estimating the frequency of Candida die-off, a Candida-specific Jarisch–Herxheimer reaction, or worsening in people outside this selected cohort.",[48,51,54],{"finding":49,"limitation":50},"The study recorded early imaging progression and corticosteroid use for suspected CDC-IRIS.","It was retrospective, had no control group, and recruited investigator-submitted cases through a registry and collaborating networks rather than population-based sampling.",{"finding":52,"limitation":53},"Five patients were treated for suspected CDC-IRIS.","IRIS had no standardized case definition or central adjudication, so 5 of 111 is not a validated incidence estimate.",{"finding":55,"limitation":56},"Imaging response was assessed during follow-up.","Follow-up timing and availability varied, and response was investigator-assigned without central blinded radiology review; the study cannot establish that nonspecific worsening predicts benefit.","No change to consumer guidance. The cohort offers a disease-specific, medically monitored example of suspected immune-reconstitution inflammation; it does not validate Candida die-off or show that worsening during a consumer intervention is beneficial.",[59],{"group":60,"route":33,"label":61},"evidence","Broad Candida claims evidence map",{"type":63,"value":64,"toc":140},"minimark",[65,73,79,85,91,97,103,109,115,121,127],[66,67,69],"content-section",{"section-key":10,"title":68},"Bottom line",[70,71,72],"p",{},"In adults treated for chronic disseminated candidiasis, early scan worsening sometimes occurred during neutrophil recovery. This is a narrow clinical context, not evidence that consumer Candida die-off is real or that worsening proves a treatment is working.",[66,74,76],{"section-key":11,"title":75},"Why this source matters",[70,77,78],{},"The cohort documents suspected immune-reconstitution inflammatory syndrome in a defined, medically managed Candida infection. It helps distinguish that clinical situation from a self-applied die-off label without changing the broader evidence verdict.",[66,80,82],{"section-key":12,"title":81},"Study and population",[70,83,84],{},"This retrospective multinational cohort included 111 adults from 19 countries with possible, probable, or proven chronic disseminated candidiasis who received antifungal treatment. Hematologic or oncologic disease was present in 109 of 111 patients (98.2%).",[66,86,88],{"section-key":13,"title":87},"What was studied",[70,89,90],{},"Researchers described treatment, response, imaging, and outcomes in submitted registry and network cases. The study did not test a randomized treatment, supplement, cleanse, restrictive diet, or consumer explanation for nonspecific symptoms.",[66,92,94],{"section-key":14,"title":93},"Results",[70,95,96],{},"The first follow-up scan was obtained at a median of 14 days (IQR 7–24). Among 74 evaluable patients, 28 (37.8%) had progression, 26 (35.1%) were stable, 17 (23.0%) improved, and 3 (4.1%) had a complete response. The authors considered early progression likely to be paradoxical worsening during neutrophil recovery rather than antifungal failure. Corticosteroids were used for suspected CDC-IRIS in 5 of 111 patients (4.5%); the reported pattern included radiological progression and persistent fever at a mean of 29 days after diagnosis. These cases were not standardized or centrally adjudicated.",[66,98,100],{"section-key":15,"title":99},"Applicability",[70,101,102],{},"These findings concern adults with diagnosed, medically treated chronic disseminated candidiasis, mostly in the setting of hematologic or oncologic disease. They do not apply to self-attributed broad Candida symptoms or show how often die-off occurs outside this selected cohort.",[66,104,106],{"section-key":16,"title":105},"Limitations",[70,107,108],{},"Retrospective registry-based case selection, no control group, variable imaging follow-up, substantial missing data, and investigator-assigned outcomes limit interpretation. Suspected IRIS had no standard definition or central adjudication. The study cannot show that nonspecific worsening predicts benefit.",[66,110,112],{"section-key":17,"title":111},"Contribution to the evidence",[70,113,114],{},"Contextual. The cohort adds a bounded example of suspected immune-reconstitution inflammation during treatment of a specific invasive Candida infection; it is not evidence for consumer die-off claims.",[66,116,118],{"section-key":18,"title":117},"Practical change",[70,119,120],{},"No practical change. This clinical cohort does not validate Candida die-off or support interpreting worsening during self-managed treatment as a sign of benefit.",[66,122,124],{"section-key":19,"title":123},"Funding and conflicts",[70,125,126],{},"No dedicated external study funding was reported. FungiScope received unrestricted registry-maintenance and infrastructure grants from Basilea Pharmaceutica, Melinta Therapeutics LLC, Mundipharma Ltd., and Pfizer Inc; the funders had no role in the study. Authors reported individual financial and professional relationships, including one patent; the remaining authors reported no manuscript-related competing interests.",[66,128,130],{"section-key":20,"title":129},"Source",[70,131,132,139],{},[133,134,138],"a",{"href":135,"rel":136},"https://pmc.ncbi.nlm.nih.gov/articles/PMC13595010/",[137],"nofollow","Read the original publication"," (published online 16 September 2026).",{"title":141,"searchDepth":142,"depth":142,"links":143},"",2,[],{"sources":145,"claims":151,"safety":152},[146],{"sourceId":27,"title":147,"canonicalId":148,"canonicalUrl":135,"publisher":149,"sourceType":150,"publicationDate":36,"lastChecked":24},"Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients","PMID:42774582; DOI:10.1016/j.eclinm.2026.104194","eClinicalMedicine","observational-study",[],[],[154,157,160],{"rel":155,"hreflang":6,"href":156},"alternate","https://candipedia.org/en/research/chronic-disseminated-candidiasis-iris-cohort-2026/",{"rel":155,"hreflang":158,"href":159},"pl-PL","https://candipedia.org/pl/research/przewlekla-rozsiana-kandydoza-iris-kohorta-2026/",{"rel":155,"hreflang":161,"href":156},"x-default",1794951393371]